國立虎尾科技大學 |

Resistance to Ibritumomab in Lymphoma

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Resistance to Ibritumomab in Lymphoma/ edited by Makoto Hosono, Jean-François Chatal.
other author:	Hosono, Makoto.
Description:	XIII, 158 p. 18 illus., 14 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Cancer research. -
Online resource:	https://doi.org/10.1007/978-3-319-78238-6
ISBN:	9783319782386

Resistance to Ibritumomab in Lymphoma
Resistance to Ibritumomab in Lymphoma[electronic resource] /edited by Makoto Hosono, Jean-François Chatal. - 1st ed. 2018. - XIII, 158 p. 18 illus., 14 illus. in color.online resource. - Resistance to Targeted Anti-Cancer Therapeutics,182196-5501 ;. - Resistance to Targeted Anti-Cancer Therapeutics,4.

Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index.

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

ISBN: 9783319782386

Standard No.: 10.1007/978-3-319-78238-6doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Resistance to Ibritumomab in Lymphoma
LDR:02369nam a22004095i 4500 001 992690
003 DE-He213
005 20200629224241.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319782386 $9 978-3-319-78238-6
024 7 $a 10.1007/978-3-319-78238-6 $2 doi
035 $a 978-3-319-78238-6
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Resistance to Ibritumomab in Lymphoma $h [electronic resource] / $c edited by Makoto Hosono, Jean-François Chatal.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a XIII, 158 p. 18 illus., 14 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 18
505 0 $a Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index.
520 $a This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
650 0 $a Cancer research. $3 1253664
650 1 4 $a Cancer Research. $3 668358
700 1 $a Hosono, Makoto. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1203438
700 1 $a Chatal, Jean-François. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1284352
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319782379
776 0 8 $i Printed edition: $z 9783319782393
776 0 8 $i Printed edition: $z 9783030086527
830 0 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 4 $3 1254768
856 4 0 $u https://doi.org/10.1007/978-3-319-78238-6
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)